Nurix Therapeutics, Inc.
Clinical trials sponsored by Nurix Therapeutics, Inc., explained in plain language.
-
New drug targets Hard-to-Treat blood cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called NX-2127 in adults with certain blood cancers (like CLL or lymphoma) that have returned or not improved after other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About …
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 00:48 UTC
-
New drug targets Hard-to-Treat blood cancers in early trial
Disease control Recruiting nowThis study tests an experimental drug called NX-5948 in adults with certain blood cancers (like CLL or lymphoma) that have come back or stopped responding to treatment. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to find a safe dose …
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 00:46 UTC
-
New pill hopes to unleash immune system against tough cancers
Disease control Recruiting nowThis early-phase study tests an experimental pill called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The drug aims to boost the body's immune system to fight tumors. The main goals are to check safety and see if the drug can shrink or c…
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New hope for Tough-to-Treat leukemia: experimental drug NX-5948 enters phase 2 trial
Disease control Recruiting nowThis study tests an experimental drug called NX-5948 (bexobrutideg) in about 100 adults whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has returned or stopped responding after treatment with BTK and BCL-2 inhibitors. The main goal is to see how many …
Phase: PHASE2 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 04, 2026 16:31 UTC
-
Healthy volunteers needed to test how food and acid reducers affect new drug
Knowledge-focused Recruiting nowThis study looks at how a new drug, NX-5948, is absorbed in the body when taken as a tablet versus a capsule, and whether food or an acid-reducing drug changes that. It involves 18 healthy adults aged 19-55. The goal is to find the best way to take the medicine, not to treat any …
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Knowledge-focused
Last updated May 17, 2026 00:47 UTC